Many new chemotherapeutic agents are under preclinical investigation and, despite efforts to more selectively target cancer cells, limitations such as toxicity and inherent resistance are often encountered. Therefore, alternative strategies are needed to treat cancer and overcome such limitations. We describe novel cyclohexylpiperazine derivatives, designed as mixed affinity ligands for sigma (s) receptors and human D8– D7 sterol isomerase (HSI) ligands, which also exhibit P-glycoprotein (P-gp) inhibitory activity, with the aim of exploiting the antiproliferative effects mediated by s and HSI sites while overcoming P-gp-mediated resistance. All of the compounds displayed high affinities for s receptors and HSI sites, P-gp inhibitory activity, and s2 receptor agonist antiproliferative activity. Antiproliferative activity was also tested in PC-3 cells to establish s1 and HSI contribution. Compound cis-11, which displayed the best antiproliferative and P-gp inhibitory activities, was coadministered with 0.1 mm doxorubicin in MDCK-MDR1 cells. Compound cis-11 caused 70% and 90% cell death when coadministered at 30 mm and 50 mm, respectively. When administered alone, cis-11 resulted in 50% cell death, demonstrating its single agent antitumor properties in a tumor cell line overexpressing P-gp.

1-Cyclohexyl-4-(4-arylcyclohexyl)piperazines: Mixed σ and human Delta8─Delta7 sterol isomerase ligands with antiproliferative and P-glycoprotein inhibitory activity

ABATE, CARMEN rosa;NISO, MAURO;CONTINO, MARIALESSANDRA;COLABUFO, Nicola Antonio;FERORELLI, Savina;PERRONE, Roberto;BERARDI, Francesco
2011

Abstract

Many new chemotherapeutic agents are under preclinical investigation and, despite efforts to more selectively target cancer cells, limitations such as toxicity and inherent resistance are often encountered. Therefore, alternative strategies are needed to treat cancer and overcome such limitations. We describe novel cyclohexylpiperazine derivatives, designed as mixed affinity ligands for sigma (s) receptors and human D8– D7 sterol isomerase (HSI) ligands, which also exhibit P-glycoprotein (P-gp) inhibitory activity, with the aim of exploiting the antiproliferative effects mediated by s and HSI sites while overcoming P-gp-mediated resistance. All of the compounds displayed high affinities for s receptors and HSI sites, P-gp inhibitory activity, and s2 receptor agonist antiproliferative activity. Antiproliferative activity was also tested in PC-3 cells to establish s1 and HSI contribution. Compound cis-11, which displayed the best antiproliferative and P-gp inhibitory activities, was coadministered with 0.1 mm doxorubicin in MDCK-MDR1 cells. Compound cis-11 caused 70% and 90% cell death when coadministered at 30 mm and 50 mm, respectively. When administered alone, cis-11 resulted in 50% cell death, demonstrating its single agent antitumor properties in a tumor cell line overexpressing P-gp.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11586/135228
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 41
social impact